Q2 EPS Estimates for Cytokinetics Reduced by Leerink Partnrs

Cytokinetics, Incorporated (NASDAQ:CYTK) – Stock analysts at Leerink Partnrs dropped their Q2 2025 EPS estimates for Cytokinetics in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst R. Ruiz now forecasts that the biopharmaceutical company will post earnings of ($1.34) per share for the quarter, down from their prior estimate of ($1.32). The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. Leerink Partnrs also issued estimates for Cytokinetics’ Q3 2025 earnings at ($1.41) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($5.69) EPS, FY2026 earnings at ($5.25) EPS, FY2027 earnings at ($3.90) EPS and FY2028 earnings at ($0.95) EPS.

Other analysts have also issued reports about the company. Barclays decreased their price objective on Cytokinetics from $55.00 to $53.00 and set an “overweight” rating for the company in a report on Thursday. Citigroup decreased their price objective on Cytokinetics from $86.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday. Royal Bank of Canada lowered their price objective on Cytokinetics from $82.00 to $80.00 and set an “outperform” rating on the stock in a research report on Wednesday. Needham & Company LLC reiterated a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a research report on Friday, May 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Cytokinetics in a report on Monday, April 21st. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.44.

Cytokinetics Stock Down 2.4 %

Shares of Cytokinetics stock opened at $31.69 on Friday. The stock’s 50-day moving average is $40.18 and its 200 day moving average is $45.96. Cytokinetics has a one year low of $31.67 and a one year high of $63.46. The firm has a market cap of $3.78 billion, a price-to-earnings ratio of -5.89 and a beta of 0.81. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.41) by $0.05. The business had revenue of $1.60 million during the quarter, compared to analyst estimates of $2.77 million. The company’s revenue was up 89.1% compared to the same quarter last year. During the same quarter last year, the company posted ($1.33) earnings per share.

Institutional Investors Weigh In On Cytokinetics

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Cytokinetics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 11,915,821 shares of the biopharmaceutical company’s stock valued at $560,520,000 after acquiring an additional 154,216 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its position in Cytokinetics by 11.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,752,123 shares of the biopharmaceutical company’s stock worth $505,780,000 after purchasing an additional 1,062,136 shares during the period. Deep Track Capital LP raised its stake in Cytokinetics by 296.9% during the 4th quarter. Deep Track Capital LP now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $117,600,000 after buying an additional 1,870,094 shares during the last quarter. Vestal Point Capital LP lifted its holdings in shares of Cytokinetics by 56.7% during the 4th quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company’s stock valued at $110,544,000 after buying an additional 850,000 shares during the period. Finally, Marshall Wace LLP lifted its holdings in shares of Cytokinetics by 14.9% during the 4th quarter. Marshall Wace LLP now owns 2,153,313 shares of the biopharmaceutical company’s stock valued at $101,292,000 after buying an additional 279,612 shares during the period.

Insider Activity at Cytokinetics

In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total value of $91,960.00. Following the sale, the executive vice president now directly owns 116,071 shares of the company’s stock, valued at approximately $5,336,944.58. The trade was a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew Callos sold 3,341 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the sale, the executive vice president now owns 64,434 shares of the company’s stock, valued at approximately $2,788,059.18. This represents a 4.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 95,362 shares of company stock worth $3,899,118 over the last 90 days. 2.70% of the stock is owned by company insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.